Following the completion of a capital increase of 4.8 million shares, which were sold to Novartis Pharma AG at an issue price of € 31.25 per share, or € 150 million in total, and admission of the new shares for trading on the Official Market of the Vienna Stock Exchange, Intercell AG, with its principal offices in Vienna, makes the following required announcement about changes in the allocation of voting rights:
Announcement of Novartis’ share in voting rights according to section 93 subsection 2 of the Austrian Stock Exchange Act:
Novartis AG has informed us that entities affiliated with Novartis AG now hold 7,244,940 shares, representing 15.9 percent of the voting rights in Intercell AG, subdivided into 4,800,000 shares (10.5%) for Novartis Pharma AG, 2,400,000 shares (5.3%) for Novartis Vaccines and Diagnostics, Inc. and 44,940 shares (0.1%) for Novartis Vaccines and Diagnostics GmbH & Co. KG.
Announcement of the total number of voting rights according to section 93 subsection 1 of the Austrian Stock Markets Act:
The total number of shares of common stock with no par value of Intercell AG, each representing one vote, has increased to 45,521,707. The share capital is now € 45,521,707.‐.
The Management Board
www.intercell.com
Intercell: Announcement of Novartis' share in voting rights
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.